At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNPX Genprex, Inc.
Closed 05-16 16:00:00 EDT
2.42
-0.08
-3.39%
盘后2.42
+0.000.00%
19:54 EDT
High2.64
Low2.34
Vol43.52K
Open2.48
D1 Closing2.51
Amplitude11.98%
Mkt Cap5.08M
Tradable Cap5.00M
Total Shares2.10M
T/O108.66K
T/O Rate2.11%
Tradable Shares2.07M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
BRIEF-Genprex Expands Clinical Trial Sites For Acclaim-3 Clinical Study Of Reqorsa Therapy In Combination With Tecentriq To Treat Small Cell Lung Cancer
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.